BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Clinical Outcome
542 results:

  • 1. National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection.
    Kameda-Smith MM; Ragulojan M; Elliott C; Bliss L; Moore H; Sader N; Alsuwaihel M; Tso MK; Dakson A; Ajani O; Yarascavitch B; Fleming A; Mehta V; Aminnejad M; Farrokhyar F; Singh SK;
    Childs Nerv Syst; 2024 May; 40(5):1339-1347. PubMed ID: 38279985
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The Application of Sodium Fluorescein in Resection of Medulloblastoma Under YELLOW 560 Filter: Feasibility and Preliminary Results of a Monocentric Cohort and Systematic Review.
    Falco J; Broggi M; Rubiu E; Schiariti M; Restelli F; Mazzapicchi E; La Corte E; Ferroli P; Acerbi F
    World Neurosurg; 2024 Mar; 183():e386-e394. PubMed ID: 38154682
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
    Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
    J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. PATIENT-RELATED FACTORS AND clinical MANAGEMENT outcomeS OF RETINOBLASTOMA IN CALABAR, NIGERIA.
    Nkanga ED; Nlemadim AC; Arazi M; Nkanga DG; Duke RE; Fabian ID; Nkanga ED; Odey FA; Meremikwu MM
    West Afr J Med; 2023 Dec; 40(12 Suppl 1):S36-S37. PubMed ID: 38070170
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
    Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Association of clinical manifestations of secondary lymphedema and lymph node dissection sites in the lower extremities of patients with melanoma.
    Chae Woon P; Kim I; Kim JH; Hwang JH
    Acta Oncol; 2023 Aug; 62(8):880-888. PubMed ID: 37656769
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
    Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
    JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
    Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
    Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
    Mandalà M; Palmieri G; Ludovini V; Baglivo S; Marasciulo F; Castiglione F; Gili A; Osella Abate S; Rubatto M; Senetta R; Avallone G; Ribero S; Romano L; Pimpinelli N; de Giorgi V; Roila F; Pisano M; Casula M; Manca A; Sini MC; Massi D; Quaglino P;
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):1991-1998. PubMed ID: 37335879
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. clinical and imaging findings for the evaluation of large Rathke's cleft cysts and cystic craniopharyngiomas.
    Yang CH; Wu CH; Lin TM; Chen ST; Tai WA; Yu KW; Luo CB; Lirng JF; Chang FC
    Pituitary; 2023 Aug; 26(4):393-401. PubMed ID: 37227614
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Predictive value and accuracy of [
    Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
    Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
    Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Using the deformity index of vital structures to predict outcome of patients with large vestibular schwannomas after Gamma Knife radiosurgery.
    Chang HC; You WC; Shen CC; Chen YJ; Sun MH; Sheu ML; Pan LY; Sheehan J; Su KC; Pan HC
    J Neurooncol; 2023 Mar; 162(1):179-189. PubMed ID: 36894719
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
    De Falco V; Suarato G; Napolitano R; Argenziano G; Famiglietti V; Amato A; Servetto A; Bianco R; Formisano L; Terrano V; Esposito A; Giugliano MC; Ciardiello D; Ciardiello F; Napolitano S; Troiani T
    Int J Cancer; 2023 Jul; 153(1):133-140. PubMed ID: 36752579
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy.
    Oertel M; Borrmann K; Baehr A; Eich HT; Greve B
    Radiat Oncol; 2022 Nov; 17(1):194. PubMed ID: 36443849
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Ambiguous melanocytic lesions: A retrospective cohort study of incidence and outcome of melanocytic tumor of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferation of uncertain significance (SAMPUS) in the Netherlands.
    Vermariën-Wang J; Doeleman T; van Doorn R; Mooyaart AL; Blokx WAM; Schrader AMR
    J Am Acad Dermatol; 2023 Mar; 88(3):602-608. PubMed ID: 36403750
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. TSPO PET signal using [
    Quach S; Holzgreve A; Kaiser L; Unterrainer M; Dekorsy FJ; Nelwan DV; Bartos LM; Kirchleitner SV; Weller J; Weidner L; Niyazi M; Ruf VC; Herms J; Stöcklein S; Wetzel C; Riemenschneider MJ; V Baumgarten L; Thon N; Brendel M; Rupprecht R; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):859-869. PubMed ID: 36329288
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis.
    Varey AHR; Williams GJ; Lo SN; Taing CY; Maurichi A; Santinami M; Scolyer RA; Thompson JF
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):859-870. PubMed ID: 36251355
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer.
    Urbaniak A; Reed MR; Heflin B; Gaydos J; Piña-Oviedo S; Jędrzejczyk M; Klejborowska G; Stępczyńska N; Chambers TC; Tackett AJ; Rodriguez A; Huczyński A; Eoff RL; MacNicol AM
    Biomed Pharmacother; 2022 Sep; 153():113440. PubMed ID: 36076555
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
    Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
    Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 28.